Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05248997) enrolled 261 people in total — 131 assigned to receive a 75 mg dose of rimegepant and 130 assigned to receive a placebo (a dummy treatment with no active ingredient). Of those, 99 in the rimegepant group and 105 in the placebo group actually received their assigned treatment, and 98 and 104 respectively completed the study. The trial was measuring symptoms of acute sinusitis (sinus pain, pressure, nasal congestion and discharge) using rating scales where participants scored their symptoms from 0 (none) to 10 (worst imaginable), and also looked at headache relief and use of additional pain relief medication within 24 hours. The reported data shows that for the primary outcome — change in facial pain/pressure/fullness two hours after taking the treatment — participants in the rimegepant group reported an average reduction of 2.70 points on the 0–10 scale, while those in the placebo group reported an average reduction of 2.61 points. For the combined nasal symptom score (a 0–30 scale adding up pain, congestion and discharge), the rimegepant group reported an average drop of 7.04 points compared with 6.74 points in the placebo group. Looking at individual symptoms at two hours, nasal congestion decreased by an average of 2.48 points (rimegepant) versus 2.25 points (placebo), and nasal discharge decreased by 1.81 points (rimegepant) versus 1.85 points (placebo). For headache relief at two hours, 59.4% of people in the rimegepant group and 55.6% in the placebo group reported their headache pain had reached a "none" or "mild" level. Regarding rescue medication use in the 24 hours after dosing, 7.3% of the rimegepant group and 10.0% of the placebo group reported taking additional pain relief. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41779821) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had at least two episodes of moderate or severe facial pain, pressure, or fullness in the past 30 days before the screening visit.
- You are willing to follow the study's rules about which medications you can take and agree not to start any new medications for sinus symptoms during the study.
- You are willing to use the study's required birth control methods during the study, and if you are a woman, you are not currently breastfeeding.
- You do not have any significant abnormal results from your medical or lab tests at screening.
Who may not be able to join:
- You have a primary headache disorder (such as migraines or tension headaches as a main diagnosis).
- You have had surgery on your nose or face in the last 6 months before screening.
- You currently have rebound nasal congestion caused by overuse of nasal decongestant sprays (confirm with trial site).
- You have been diagnosed with, or are suspected of having, an invasive fungal sinus infection.
- You are currently receiving aspirin desensitization or ongoing aspirin therapy for Samter's Triad (a condition involving aspirin sensitivity, asthma, and nasal polyps).
- You have a history of getting four or more separate bacterial sinus infections per year, with no sinus symptoms between those episodes.
- Your Body Mass Index (BMI) is higher than 35.
- You have a history of certain serious health conditions, including HIV, heart or blood vessel disease, uncontrolled high blood pressure or diabetes, psychiatric conditions, drug or alcohol misuse, cancer, significant drug allergies, or other major unstable health conditions.
- You are currently taking or using any medications or treatments that are not allowed by the study.
- You are currently taking part in another clinical trial involving an experimental (non-biological) treatment or procedure.
- You have previously taken part in a study involving the drug BHV-3000, BMS-927711, or rimegepant.
- You are planning to join another investigational clinical trial at the same time as this one.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.